d4cdfd13-829c-4f29-984b-5a8897437e3e
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.400
- G2M_CHECKPOINT+0.400
- MITOTIC_SPINDLE+0.400
- TGF_BETA_SIGNALING+0.400
- UV_RESPONSE_DN+0.400
- ANDROGEN_RESPONSE+0.300
- E2F_TARGETS+0.300
- KRAS_SIGNALING_UP+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.200
- IL6_JAK_STAT3_SIGNALING+0.200
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.300
- INTERFERON_ALPHA_RESPONSE-0.300
- PANCREAS_BETA_CELLS-0.300
- APICAL_SURFACE-0.200
- CHOLESTEROL_HOMEOSTASIS-0.200
- ESTROGEN_RESPONSE_LATE-0.200
- INTERFERON_GAMMA_RESPONSE-0.200
- KRAS_SIGNALING_DN-0.200
- MYOGENESIS-0.200
- OXIDATIVE_PHOSPHORYLATION-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613747 | — | D | 0.735 |
| 2 | MDT-AP-3043 | Med | Medulloblastoma | 0.708 |
| 3 | 5472fa65-a8e2-4593-abd8-e241d1bdec84 | — | — | 0.685 |
| 4 | SRR23303749 | — | — | 0.684 |
| 5 | TCGA-DK-A3IN-01A-11R-A20F-07 | — | — | 0.681 |
| 6 | TCGA-A8-A097-01A-11R-A034-07 | — | C | 0.679 |
| 7 | TCGA-BH-A18P-01A-11R-A12D-07 | — | A | 0.672 |
| 8 | MNG285 | — | — | 0.670 |
| 9 | f5e6497a-ed39-408d-9034-a965baaafbf7 | — | — | 0.649 |
| 10 | 21e5a870-f00c-4bb9-a1bf-66291ab0d80a | — | — | 0.644 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.400 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |